Dane Leone
Stock Analyst at Raymond James
(2.17)
# 1,219
Out of 4,479 analysts
68
Total ratings
38.36%
Success rate
-4.13%
Average return
Main Sectors:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $10.75 | +318.60% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $110.36 | -9.39% | 4 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $37.38 | -19.74% | 1 | Nov 16, 2023 | |
| BLUE bluebird bio | Maintains: Outperform | $10 → $13 | $0.92 | +1,308.30% | 5 | Nov 8, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $1,044.66 | -9.06% | 7 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $5.26 | +147.15% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $24.91 | +84.66% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $25.34 | +172.30% | 4 | May 8, 2023 | |
| GTHX G1 Therapeutics | Maintains: Outperform | $24 → $8 | $2.45 | +226.53% | 4 | May 4, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $6.47 | +348.22% | 2 | Apr 19, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $0.88 | +809.09% | 2 | Nov 10, 2022 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $31 → $13 | $0.89 | +1,360.67% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $6.68 | +109.58% | 3 | Nov 8, 2022 | |
| XNCR Xencor | Upgrades: Strong Buy | $58 | $18.26 | +217.63% | 2 | Oct 13, 2022 | |
| SLP Simulations Plus | Maintains: Outperform | $54 → $70 | $46.86 | +49.38% | 2 | Aug 29, 2022 | |
| ALLO Allogene Therapeutics | Downgrades: Market Perform | n/a | $2.16 | - | 5 | Aug 10, 2022 | |
| CYTK Cytokinetics | Maintains: Outperform | $54 → $63 | $54.84 | +14.88% | 2 | Aug 5, 2022 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $40.45 | - | 3 | Jun 6, 2022 | |
| CRIS Curis | Downgrades: Market Perform | n/a | $6.25 | - | 2 | Apr 5, 2022 | |
| TARS Tarsus Pharmaceuticals | Maintains: Strong Buy | n/a | $27.55 | - | 2 | Oct 8, 2021 | |
| SAGE Sage Therapeutics | Downgrades: Market Perform | n/a | $10.82 | - | 1 | Dec 1, 2020 | |
| AMGN Amgen | Upgrades: Outperform | n/a | $310.77 | - | 3 | Oct 26, 2020 | |
| VYGR Voyager Therapeutics | Assumes: Buy | n/a | $7.59 | - | 2 | Sep 10, 2018 | |
| JNJ Johnson & Johnson | Downgrades: Sell | n/a | $146.03 | - | 1 | Jul 21, 2017 |
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $10.75
Upside: +318.60%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $110.36
Upside: -9.39%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $37.38
Upside: -19.74%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $10 → $13
Current: $0.92
Upside: +1,308.30%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $1,044.66
Upside: -9.06%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $5.26
Upside: +147.15%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $24.91
Upside: +84.66%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $25.34
Upside: +172.30%
G1 Therapeutics
May 4, 2023
Maintains: Outperform
Price Target: $24 → $8
Current: $2.45
Upside: +226.53%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $6.47
Upside: +348.22%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $0.88
Upside: +809.09%
Xilio Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $31 → $13
Current: $0.89
Upside: +1,360.67%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $6.68
Upside: +109.58%
Xencor
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $18.26
Upside: +217.63%
Simulations Plus
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $46.86
Upside: +49.38%
Allogene Therapeutics
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.16
Upside: -
Cytokinetics
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $54.84
Upside: +14.88%
Bristol-Myers Squibb Company
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $40.45
Upside: -
Curis
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $6.25
Upside: -
Tarsus Pharmaceuticals
Oct 8, 2021
Maintains: Strong Buy
Price Target: n/a
Current: $27.55
Upside: -
Sage Therapeutics
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $10.82
Upside: -
Amgen
Oct 26, 2020
Upgrades: Outperform
Price Target: n/a
Current: $310.77
Upside: -
Voyager Therapeutics
Sep 10, 2018
Assumes: Buy
Price Target: n/a
Current: $7.59
Upside: -
Johnson & Johnson
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $146.03
Upside: -